1 Waks, A. G. & Winer, E. P. Breast Cancer Treatment: A Review. JAMA 321, 288-300, doi:10.1001/jama.2018.19323 (2019).
2 Criscitiello, C., Azim, H. A., Jr., Schouten, P. C., Linn, S. C. & Sotiriou, C. Understanding the biology of triple-negative breast cancer. Ann Oncol 23 Suppl 6, vi13-18, doi:10.1093/annonc/mds188 (2012).
3 Denkert, C., Liedtke, C., Tutt, A. & von Minckwitz, G. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. The Lancet 389, 2430-2442, doi:10.1016/s0140-6736(16)32454-0 (2017).
4 Metzger-Filho, O. et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30, 1879-1887, doi:10.1200/JCO.2011.38.2010 (2012).
5 Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121, 2750-2767, doi:10.1172/JCI45014 (2011).
6 Burstein, M. D. et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 21, 1688-1698, doi:10.1158/1078-0432.CCR-14-0432 (2015).
7 Jiang, Y. Z. et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell 35, 428-440 e425, doi:10.1016/j.ccell.2019.02.001 (2019).
8 Belli, C., Duso, B. A., Ferraro, E. & Curigliano, G. Homologous recombination deficiency in triple negative breast cancer. Breast 45, 15-21, doi:10.1016/j.breast.2019.02.007 (2019).
9 Brown, J. S., O'Carrigan, B., Jackson, S. P. & Yap, T. A. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov 7, 20-37, doi:10.1158/2159-8290.CD-16-0860 (2017).
10 Yang, H. et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297, 1837-1848, doi:10.1126/science.297.5588.1837 (2002).
11 Pellegrini, L. et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420, 287-293, doi:10.1038/nature01230 (2002).
12 Lord, C. J. & Ashworth, A. PARP inhibitors: Synthetic lethality in the clinic. Science 355, 1152-1158, doi:10.1126/science.aam7344 (2017).
13 Ashworth, A. & Lord, C. J. Synthetic lethal therapies for cancer: what's next after PARP inhibitors? Nat Rev Clin Oncol 15, 564-576, doi:10.1038/s41571-018-0055-6 (2018).
14 Timms, K. M. et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 16, 475, doi:10.1186/s13058-014-0475-x (2014).
15 Abkevich, V. et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107, 1776-1782, doi:10.1038/bjc.2012.451 (2012).
16 Birkbak, N. J. et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2, 366-375, doi:10.1158/2159-8290.Cd-11-0206 (2012).
17 Popova, T. et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 72, 5454-5462, doi:10.1158/0008-5472.Can-12-1470 (2012).
18 Telli, M. L. et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res 22, 3764-3773, doi:10.1158/1078-0432.Ccr-15-2477 (2016).
19 Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70, doi:10.1038/nature11412 (2012).
20 Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399, doi:10.1038/nature10933 (2012).
21 Foulkes, W. D. et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95, 1482-1485, doi:10.1093/jnci/djg050 (2003).
22 Gong, Y. et al. Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. Cell Metab 33, 51-64.e59, doi:10.1016/j.cmet.2020.10.012 (2021).
23 Jiang, Y. Z. et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell 35, 428-440.e425, doi:10.1016/j.ccell.2019.02.001 (2019).
24 Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47, doi:10.1093/nar/gkv007 (2015).
25 Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284-287, doi:10.1089/omi.2011.0118 (2012).
26 Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw 33, 1-22 (2010).
27 Xiao, Y. et al. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. Clin Cancer Res 25, 5002-5014, doi:10.1158/1078-0432.CCR-18-3524 (2019).
28 Tutt, A. & Ashworth, A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 8, 571-576, doi:10.1016/s1471-4914(02)02434-6 (2002).
29 Sharma, P. et al. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Ann Oncol 29, 654-660, doi:10.1093/annonc/mdx821 (2018).
30 Mayerhoefer, M. E. et al. Introduction to Radiomics. J Nucl Med 61, 488-495, doi:10.2967/jnumed.118.222893 (2020).
31 Liu, Z. et al. The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges. Theranostics 9, 1303-1322, doi:10.7150/thno.30309 (2019).
32 Gillies, R. J., Kinahan, P. E. & Hricak, H. Radiomics: Images Are More than Pictures, They Are Data. Radiology 278, 563-577, doi:10.1148/radiol.2015151169 (2016).
33 Aerts, H. J. et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5, 4006, doi:10.1038/ncomms5006 (2014).
34 Liu, Z. et al. Predicting distant metastasis and chemotherapy benefit in locally advanced rectal cancer. Nat Commun 11, 4308, doi:10.1038/s41467-020-18162-9 (2020).
35 Huang, Y. Q. et al. Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer. J Clin Oncol 34, 2157-2164, doi:10.1200/JCO.2015.65.9128 (2016).
36 Sun, R. et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 19, 1180-1191, doi:10.1016/S1470-2045(18)30413-3 (2018).
37 Trebeschi, S. et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol 30, 998-1004, doi:10.1093/annonc/mdz108 (2019).
38 Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921, doi:10.1038/nature03445 (2005).
39 Robson, M. et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 377, 523-533, doi:10.1056/NEJMoa1706450 (2017).
40 Tutt, A. N. J. et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med 384, 2394-2405, doi:10.1056/NEJMoa2105215 (2021).
41 Minckwitz, G. V. et al. Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto. Journal of Clinical Oncology 33, 1004-1004, doi:10.1200/jco.2015.33.15_suppl.1004 (2015).
42 Tutt, A. et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 24, 628-637, doi:10.1038/s41591-018-0009-7 (2018).
43 Jiang, Y. Z. et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res 31, 178-186, doi:10.1038/s41422-020-0375-9 (2021).
44 Gong, Y. et al. Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. Cell Metab 33, 51-64 e59, doi:10.1016/j.cmet.2020.10.012 (2021).